Compare ANAB & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANAB | INSP |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2015 | 2018 |
| Metric | ANAB | INSP |
|---|---|---|
| Price | $60.37 | $42.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 16 |
| Target Price | $71.67 | ★ $94.00 |
| AVG Volume (30 Days) | 586.1K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.02 | ★ 179.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | $82,050,000.00 |
| Revenue This Year | N/A | $8.02 |
| Revenue Next Year | $52.14 | $8.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 157.01 | 62.18 |
| 52 Week Low | $17.11 | $39.61 |
| 52 Week High | $73.30 | $148.55 |
| Indicator | ANAB | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 35.83 |
| Support Level | $53.46 | N/A |
| Resistance Level | $67.69 | $59.40 |
| Average True Range (ATR) | 4.38 | 2.69 |
| MACD | -0.93 | -0.41 |
| Stochastic Oscillator | 19.86 | 17.65 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.